Gilead Sciences Inc. (GILD)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
81.52+0.05 (+0.06%)
As of 2:14 PM EDT. Market open.
People also watch:
CELGBIIBAMGNREGNFB
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open81.47
Prev Close81.47
Bid81.62 x 300
Ask81.63 x 700
Day's Range81.27 - 82.10
52wk Range77.92 - 113.31
1y Target EstN/A
Market Cap107.58B
P/E Ratio (ttm)7.15
Beta0.99
Volume5,160,390
Avg Vol (3m)10,176,060
Dividend & Yield1.88 (2.32%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • TheStreet.com3 hours ago

    Gilead (GILD) Price Target Cut Amid Weak Outlook for HIV Drug Sales

    Leerink trimmed its price target on Gilead Sciences (GILD) stock today as it anticipates lower revenue from HIV sales in the future.

  • Barrons.com4 hours ago

    Gilead Sciences: It's Not Just Hepatitis C That's Disappointing

    Shares of Gilead Sciences (GILD) have dropped 19% so far this year thanks to disappointing sales of its hepatitis-C treatments. Now, Leerink's Geoffrey Porges and Bradley Canino have cut their price target on the biotech giant thanks to signs that its new HIV drug sales haven't been as strong as they originally modeled. As a result of our updates, we continue to expect Gilead’s domestic HIV volume to grow steadily and sustainably but now forecast a slightly lower Revenue/TRx trend given slower-than-expected switching to TAF based regimens from legacy combinations.

  • Why You Should (and Shouldn't) Buy Gilead Sciences, Inc.
    Motley Fool6 hours ago

    Why You Should (and Shouldn't) Buy Gilead Sciences, Inc.

    Should investors take advantage of Gilead's year-long sell-off, or should they remain on the sidelines?